drugset / Trial / NCT06605651

Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR.

NCT06605651 ↗

Phase 2 Not yet recruiting 100 enrolled Phagenix
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Total joint replacements are effective for chronic pain but can lead to Prosthetic Joint Infections (PJI), primarily caused by Staphylococcus aureus and resistant to antibiotics. Standard treatment involves DAIR surgery and antibiotics, but there's a need for better solutions due to rising infections and antibiotic resistance. Bacteriophage therapy, which targets specific bacteria, shows promise. Phaxiam Therapeutics is studying the safety and efficacy of phage therapy in treating Staphylococcus aureus infections in hip or knee PJI patients undergoing DAIR.

Timeline

Start
2026-07
Primary completion
2028-03
Completion
2029-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PP1493 Other / unclassified — Other
Subject PP1815 Other / unclassified — Other